ArticleJournal of medical biochemistry2026
Clinical significance of coagulation biomarkers in venous pressure therapy for preventing lower-extremity deep venous thromboembolism: A meta-analysis.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate the biochemical and clinical significance of venous pressure therapy in preventing venous thromboembolism (VTE) through analysis of coagulation and fibrinolysis biomarkers, including fibrinogen (FIB), D-dimer (D-D), and activated partial thromboplastin time (APTT). Methods: Randomized controlled trials published between 2013 and 2025 were systematically retrieved from PubMed, CNKI, VIP, and Wanfang databases. Eligible studies investigated venous pressure therapy and reported coagulation-related indices. Pooled effect sizes were calculated for key biochemical markers (FIB, D-D, APTT, PT, TT) and venous hemodynamic outcomes. Results: Nineteen clinical studies met inclusion criteria. Meta-analysis revealed that venous pressure therapy significantly reduced plasma FIB and D-D levels, prolonged APTT, prothrombin time (PT), and thrombin time (TT), and improved venous blood flow velocity. These changes reflect improved anticoagulant activity, enhanced fibrinolysis, and reduced risk of thrombosis. Importantly, the observed modulation of biochemical markers correlated with a lower incidence of lower-extremity deep venous thrombosis. Conclusions: Venous pressure therapy favorably alters coagulation and fibrinolytic biomarkers, underscoring their diagnostic value in monitoring therapeutic efficacy and thrombotic risk. These findings highlight the critical role of laboratory indices in guiding the prevention and management of VTE, supporting their integration into standardized clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.